PMID- 25756551
OWN - NLM
STAT- MEDLINE
DCOM- 20160115
LR  - 20221207
IS  - 1473-5857 (Electronic)
IS  - 0268-1315 (Linking)
VI  - 30
IP  - 3
DP  - 2015 May
TI  - Improvement in verbal memory following SSRI augmentation of antipsychotic 
      treatment is associated with changes in the expression of mRNA encoding for the 
      GABA-A receptor and BDNF in PMC of schizophrenic patients.
PG  - 158-66
LID - 10.1097/YIC.0000000000000070 [doi]
AB  - Verbal memory impairment in schizophrenia is associated with abnormalities in 
      gamma-aminobutyric acid (GABA)-ergic and brain-derived neurotrophic factor (BDNF) 
      systems. Recent evidence from animal and clinical studies that adding fluvoxamine 
      to antipsychotics alters the expression of transcripts encoding for the GABA-A 
      receptor and BDNF led us to postulate that fluvoxamine augmentation may improve 
      memory in schizophrenia. To test this, we examined the effect of add-on 
      fluvoxamine on verbal memory and other cognitive functions and related it to the 
      expression of mRNA coding for the GABA-A receptor and BDNF in peripheral 
      mononuclear cells (PMC) of schizophrenic patients. Twenty-nine patients completed 
      a 6-week study in which fluvoxamine (100 mg/day) was added to ongoing 
      antipsychotic treatment. Verbal memory, abstraction working memory, object and 
      face recognition, and psychomotor speed and clinical symptoms were assessed at 
      baseline and after 3 and 6 weeks of treatment. Blood samples were taken at 
      baseline and weeks 1, 3, and 6 and PMC was assayed for the GABA-A beta3 receptor 
      and BDNF mRNA by quantitative real-time reverse transcription-PCR. Associative 
      and logical verbal memory improved significantly and showed a significant 
      correlation with changes in PMC BDNF and GABA-A beta3 receptor mRNA, which 
      increased during treatment. Abstraction and object recognition improved, but this 
      did not correlate with PMC measures. Negative and positive symptoms improved 
      significantly; the latter showed significant correlations with changes in PMC 
      measures. Addition of fluvoxamine to antipsychotics improves verbal memory. It is 
      postulated that the mechanism involves enhanced GABA-A receptor/BDNF-dependent 
      synaptic plasticity in the hippocampus.
FAU - Silver, Henry
AU  - Silver H
AD  - aMolecular Neuropsychiatry Unit bClinical Research Unit, Sha'ar Menashe Brain 
      Behavior Laboratory, Sha'ar Menashe Mental Health Center cEve Topf and National 
      Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases 
      Research, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 
      Haifa, Israel dDepartment of Biostatistics and Epidemiology, University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Mandiuk, Nina
AU  - Mandiuk N
FAU - Einoch, Reef
AU  - Einoch R
FAU - Susser, Ehud
AU  - Susser E
FAU - Danovich, Lena
AU  - Danovich L
FAU - Bilker, Warren
AU  - Bilker W
FAU - Youdim, Moussa
AU  - Youdim M
FAU - Weinreb, Orly
AU  - Weinreb O
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, GABA-A)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - O4L1XPO44W (Fluvoxamine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluvoxamine/administration & dosage
MH  - Gene Expression Regulation
MH  - Humans
MH  - Leukocytes, Mononuclear/drug effects/*metabolism
MH  - Male
MH  - Memory/*drug effects/physiology
MH  - RNA, Messenger/biosynthesis
MH  - Receptors, GABA-A/*biosynthesis
MH  - Schizophrenia/*blood/drug therapy
MH  - Selective Serotonin Reuptake Inhibitors/*administration & dosage
MH  - Treatment Outcome
MH  - Verbal Learning/drug effects/physiology
MH  - Young Adult
EDAT- 2015/03/11 06:00
MHDA- 2016/01/16 06:00
CRDT- 2015/03/11 06:00
PHST- 2015/03/11 06:00 [entrez]
PHST- 2015/03/11 06:00 [pubmed]
PHST- 2016/01/16 06:00 [medline]
AID - 10.1097/YIC.0000000000000070 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2015 May;30(3):158-66. doi: 
      10.1097/YIC.0000000000000070.